[1] Moosavy SH,Davoodian P,Nazarnezhad MA,et al. Epidemiology, transmission, diagnosis, and outcome of Hepatitis C virus infection. Electron Physician, 2017, 9: 5646-5656.
[2] Ferri C,Giuggioli D,Colaci M. Renal manifestations of hepatitis C virus. Clin Liver Dis, 2017, 21: 487-497.
[3] Shahab O,Golabi P,Younossi ZM. Chronic kidney disease in patients with chronic hepatitis C virus infection. Minerva Gastroenterol Dietol, 2018.
[4] Harfouche M,Chemaitelly H,Mahmud S,et al. Epidemiology of hepatitis C virus among hemodialysis patients in the Middle East and North Africa: systematic syntheses, meta-analyses, and meta-regressions. Epidemiol Infect, 2017, 145: 3243-3263.
[5] Spengler U. Direct antiviral agents (DAAs) - A new age in the treatment of hepatitis C virus infection. Pharmacol Ther, 2018, 183: 118-126.
[6] Kesiraju S,Srikanti P,Sahariah S. Hepatitis C infection in renal transplantation: pathogenesis, current impact and emerging trends. Virusdisease, 2017, 28: 233-241.
[7] Maughan A,Ogbuagu O. Pegylated interferon alpha 2a for the treatment of hepatitis C virus infection. Expert Opin Drug Metab Toxicol, 2018, 14: 219-227.
[8] Halota W,Flisiak R,Juszczyk J,et al. Recommendations for the treatment of hepatitis C in 2017. Clin Exp Hepatol, 2017, 3: 47-55.
[9] Jakobsen JC,Nielsen EE,Feinberg J,et al. Direct-acting antivirals for chronic hepatitis C. Cochrane Database Syst Rev, 2017, 9: CD012143.
[10] Cox-North P,Hawkins KL,Rossiter ST,et al. Sofosbuvir-based regimens for the treatment of chronic hepatitis C in severe renal dysfunction. Hepatol Commun, 2017, 1: 248-255.
[11] Choudhary NS,Kumar A,Bodh V,et al. Efficacy and safety of sofosbuvir-based regimens in chronic hepatitis C patients on dialysis. Indian J Gastroenterol, 2017, 36: 113-116.
[12] Sperl J,Frankova S,Kreidlova M,et al. Combination of sofosbuvir and daclatasvir in the treatment of genotype 3 chronic hepatitis C virus infection in patients on maintenance hemodialysis. Ther Clin Risk Manag, 2017, 13: 733-738.
[13] Fernandes AR,Laranjinha IJ,Birne R,et al. HCV-infected renal transplant recipients: our experience before the availability of new antiviral drugs. Int J Organ Transplant Med, 2017, 8: 104-109.
[14] Heo NY,Mannalithara A,Kim D,et al. Long-term patient and graft survival of kidney transplant recipients with hepatitis C virus infection in the united States. Transplantation, 2018, 102: 454-460.
[15] Okumi M,Unagami K,Kakuta Y,et al. Elderly living donor kidney transplantation allows worthwhile outcomes: The Japan Academic Consortium of Kidney Transplantation study. Int J Urol, 2017, 24: 833-840.
[16] Hanif FM,Laeeq SM,Luck NH,et al. Posttransplant de novo hepatitis C virus infection in renal transplant recipients: its impact on morbidity and mortality. Exp Clin Transplant, 2017, 15: 56-60.
[17] Trotter PB,Summers DM,Ushiro-Lumb I,et al. Use of organs from hepatitis C virus positive donors for uninfected recipients: a potential cost-effective approach to save lives. Transplantation, 2018, 102: 664-672
[18] Gupta G,Kang L,Yu JW,et al. Long-term outcomes and transmission rates in hepatitis C virus-positive donor to hepatitis C virus-negative kidney transplant recipients: Analysis of United States national data. Clin Transplant, 2017, 31. doi: 10.1111/ctr.13055.
[19] Cohen JB,Eddinger KC,Shelton B,et al. Effect of kidney donor hepatitis C virus serostatus on renal transplant recipient and allograft outcomes. Clin Kidney J, 2017, 10: 564-572.
[20] McCauley M,Mussell A,Goldberg D,et al. Race, risk, and willingness of end-stage renal disease patients without hepatitis C (HCV) to accept an HCV-infected kidney transplant. Transplantation, 2018, 102: e163-e170.
[21] Chen K,Lu P,Song R,et al. Direct-acting antiviral agent efficacy and safety in renal transplant recipients with chronic hepatitis C virus infection: A PRISMA-compliant study. Medicine (Baltimore), 2017, 96: e7568.
[22] Fernandez-Ruiz M,Polanco N,Garcia-Santiago A,et al. Impact of anti-HCV direct antiviral agents on graft function and immunosuppressive drug levels in kidney transplant recipients: a call to attention in the mid-term follow-up in a single-center cohort study. Transpl Int, 2018, doi: 10.1111/tri.13118.
[23] Colombo M,Aghemo A,Liu H,et al. Treatment with ledipasvir-sofosbuvir for 12 or 24 weeks in kidney transplant recipients with chronic hepatitis C virus genotype 1 or 4 infection: A Randomized Trial. Ann Intern Med, 2017, 166: 109-117.
[24] Xue Y,Zhang LX,Wang L,et al. Efficacy and safety of sofosbuvir and daclatasvir in treatment of kidney transplantation recipients with hepatitis C virus infection. World J Gastroenterol, 2017, 23: 5969-5976.
[25] Fernandez I,Munoz-Gomez R,Pascasio JM,et al. Efficacy and tolerability of interferon-free antiviral therapy in kidney transplant recipients with chronic hepatitis C. J Hepatol, 2017, 66: 718-723.
[26] Hanif FM,Laeeq SM,Mandhwani RK,et al. Effectiveness of sofosbuvir and ribavirin for eradicating hepatitis C virus in renal transplant recipients in pakistan: where resources are scarce. Exp Clin Transplant, 2017, 15(Suppl 1): 63-67.
[27] Taneja S,Duseja A,De A,et al. Successful treatment of chronic hepatitis C infection with directly acting antivirals in renal transplant recipients. Nephrology (Carlton), 2017.
[28] Saxena V,Khungar V,Verna EC,et al. Safety and efficacy of current direct-acting antiviral regimens in kidney and liver transplant recipients with hepatitis C: Results from the HCV-TARGET study. Hepatology, 2017, 66: 1090-1101.
[29] Dharancy S,Coilly A,Fougerou-Leurent C,et al. Direct-acting antiviral agent-based regimen for HCV recurrence after combined liver-kidney transplantation: Results from the ANRS CO23 CUPILT study. Am J Transplant, 2017, 17: 2869-2878. |
